Association of Treatment With Nirmatrelvir and the Risk of Post–COVID-19 Condition (PCC)
In this cohort study of 281 793 people with SARS-CoV-2 infection and at least 1 risk factor for progression to severe COVID-19 illness, treatment with nirmatrelvir during the acute phase of COVID-19 was associated with reduced risk of PCC, including reduced risk of 10 of 13 post–acute sequelae in various organ systems, as well as reduced risk of post–acute death and post–acute hospitalization. Nirmatrelvir was associated with reduced risk of PCC in people who were unvaccinated, vaccinated, and boosted, and in people with primary SARS-CoV-2 infection and reinfection. Full Access: JAMA
Communication Failures, Policy Noncompliance Fuel Jump In Reported Patient Safety Events, Joint Commission Finds
Reports of serious patient safety events among healthcare facilities in 2022 rose 19% from 2021 with falls, the most common such event, rising nearly 27%, according to data reported to The Joint Commission and recently released. Full Access: Fierce Healthcare
Final Data Shows Pfizer RSV Vaccine 82 Percent Effective In Infants When Given To Pregnant Mothers
An experimental vaccine for respiratory syncytial virus (RSV) was found to be 82 percent effective for infants when given to pregnant mothers, he study released Wednesday said that while the shot was successful in preventing severe cases of the illness, it did not reach its goal of more effectively preventing non-severe cases of the virus. It also said there were no safety concerns identified in the vaccine. Full Access: The Hill
Update on Vaccine-Derived Poliovirus Outbreaks — Worldwide, January 2021–December 2022
Lower vaccination rates led to a global surge in cases of one type of vaccine-derived polio last year. According to the report, the proportion of cVDPV cases caused by cVDPV1 increased from 3% in 2020 to 18% in 2022 following “a substantial decrease in global routine immunization coverage and suspension of preventive immunization campaigns Full Access: CDC
